To prevent the nausea and vomiting associated with motion sickness, a dose of one Transderm Scop patch (formulated to deliver approximately 1mg of scopolamine over 3 days) should be applied to the hairless area behind one ear at least 4 hours before the antiemetic effect is required. To prevent postoperative nausea and vomiting, a dose of one Transderm Scop patch should be applied the evening before scheduled surgery, except for caesarian section.
What Drugs, Substances, or Supplements Interact with Transderm Scop?
Transderm Scop may interact with other medicines that make you sleepy (such as cold or allergy medicines, sedatives, narcotic pain medicines, sleeping pills, muscle relaxers, and medicines for seizures, depression, or anxiety). Transderm Scop slows the digestive tract, which can make it harder for your body to absorb any medicines you take by mouth. Tell your doctor all medications and supplements you use.
Transderm Scop During Pregnancy and Breastfeeding
Tell your doctor if you are pregnant or plan to become pregnant while using Transderm Scop; it is unknown if Transderm Scop transdermal will harm a fetus. Transderm Scop passes into breast milk and may harm a nursing baby. Consult your doctor before breastfeeding
Additional Information
Our Transderm scop Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
Transderm Scop Consumer Information
Get emergency medical help if you have signs of an allergic reaction: hives, rash, skin redness; difficulty breathing; swelling of your face, lips, tongue, or throat.
Remove the skin patch and call your doctor at once if you have:
severe dizziness;
confusion, agitation, extreme fear, hallucinations, unusual thoughts or behavior;
a seizure;
eye pain or redness, blurred vision, dilated pupils;
decreased urination, painful or difficult urination; or
stomach pain, nausea, vomiting.
Serious side effects may be more likely in older adults.
Common side effects may include:
dry mouth, sore throat;
blurred vision or other eye problems;
drowsiness, dizziness;
confusion; or
feeling agitated or irritable.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
Motion Sickness
The most common adverse reaction (approximately two thirds) was dry mouth. Less common adverse reactions, included drowsiness (less than one sixth), blurred vision and dilation of the pupils.
PONV
Common adverse reactions, occurring in at least 3% of patients in PONV clinical trials are shown in Table 1.
Table 1 Common Adverse Reactions* in Surgical Patients for the Prevention of PONV
Transderm Scop % (N = 461)
Placebo % (N = 457)
Dry mouth
29
16
Dizziness
12
7
Somnolence
8
4
Agitation
6
4
Visual Impairment
5
3
Confusion
4
3
Mydriasis
4
0
Pharyngitis
3
2
*occurring in at least 3% of patients and at a rate higher than placebo
Postmarketing Experience
The following adverse reactions have been identified during post-approval use of scopolamine transdermal system. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Psychiatric disorders: acute psychosis including: hallucinations, disorientation, and paranoia
Nervous system disorders: headache, amnesia, coordination abnormalities, speech disorder, disturbance in attention, restlessness
General disorders and administration site conditions: application site burning
&Copy; Transderm Scop Patient Information is supplied by Cerner Multum, Inc. and Transderm Scop Consumer information is supplied by First Databank, Inc., used under license and subject to their respective copyrights.
